Lessons learned from successful Papanicolaou cytology cervical cancer prevention in the socialist republic of Vietnam

Diagnostic Cytopathology

Volumn 40, Issue 4, 2012, Pages 355-366

  Suba, Eric J ^a   Raab, Stephen S ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Bill Melinda Gates Foundation; cervical cancer prevention; developing countries; HPV vaccines; Papanicolaou cytology screening

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; WART VIRUS VACCINE;

ANAPHYLAXIS; ARTICLE; AUTOIMMUNE DISEASE; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DRUG EFFICACY; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MOTOR NEURON DISEASE; MYELITIS; PANCREATITIS; PAPANICOLAOU TEST; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VENOUS THROMBOEMBOLISM; VIET NAM; WART VIRUS;

CERVIX UTERI; FEMALE; GAME THEORY; HUMANS; SOCIAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIETNAM; WORLD HEALTH;

EID: 84859048252     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21655     Document Type: Article

References (103)

1. Guzick DS,. Efficacy of screening for cervical cancer: A review. Am J Public Health 1978; 68: 125-134. (Pubitemid 8297535)
2. Suba EJ,. The Viet/American Cervical Cancer Prevention Project: 1994, 1995, and 1997 summary reports. Unpublished manuscripts. United States Copyright Office registration number: TXu000841840. United States Copyright Office registration date: February 2, 1998. Hard copies available on request from:. Redacted 1997 summary report available at: [last accessed November 1, 2010 ].
3. Quoc NM, Hung NC, Parkin DM,. Cancer incidence in Ho Chi Minh City, Vietnam, 1995-1996. Int J Cancer 1998; 76: 472-479. (Pubitemid 28227987)
4. Hoang Anh PT, Parkin DM, Hanh NT, Duc NB,. Cancer in the population of Hanoi, Vietnam, 1988-1990. Br J Cancer 1993; 68: 1236-1242. (Pubitemid 23356683)
5. Huynh ML, Raab SS, Suba EJ,. Association between war and cervical cancer among Vietnamese women. Int J Cancer 2004; 110: 775-777. (Pubitemid 38746038)
6. Easterly W,. The white man's burden: Why the West's efforts to aid the Rest have done so much ill and so little good. New York: Penguin Press; 2006.
7. Suba EJ, Murphy SK, Donnelly AD, Furia LM, Huynh ML, Raab SS,. Viet/American Cervical Cancer Prevention Project. Systems analysis of real-world obstacles to successful cervical cancer prevention in developing countries. Am J Public Health 2006; 96: 480-487. (Pubitemid 43320694)
8. Raab SS, Xuan LV, Trung NS, et al. Breast fine needle aspiration in the Socialist Republic of Vietnam: First year experience in the Ho Chi Minh City Cancer Center. The Breast Journal 1996; 2: 299-303. (Pubitemid 126734508)
9. Suba EJ, Hung NC, Duc NB, Raab SS,. Viet/American Cervical Cancer Prevention Project. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. Cancer 2001; 91: 928-939.
10. California State Attorney General Registry of Charitable Trusts. The Viet/American Cervical Cancer Prevention Project; FEIN 943245978. Available at: [last accessed November 1, 2010 ].
11. Hùng NC, Mǎn PD, Minh LH, Dung PX, Thinh DHQ, Tùng BD,. Gánh nǎng ung thu' tȧi Thành Phô Hô Chí Minh. Y Hoc Thành Phô Hô Chí Minh. Tâp 10. Phu bȧn cuia Sô 4, 2006. Available at: [last accessed November 1, 2010 ].
12. Hùng NC, Minh LH, Dung PX, Thinh DHQ,. Giȧi quyêt gánh nǎng ung thu' cho Thành Phô Hô Chí Minh. Y Hoc Thành Phô Hô Chí Minh. Tâp 12. Phu bȧn cuia Sô 4, 2008. Available at: [last accessed November 1, 2010 ].
13. Tùng BD, Khánh QT, Nam NH, Khánh TN, Tính HT, Dô HC, Thinh DHQ, Dung PX, Minh LH,. Báo cáo ghi nhân ung thu' quǎn thǎ tai Thành Phô Hô Chí Minh tú' nâm 2003 Dên nâm 2006. Hôi Thȧo Quôc Gia Phéng Chông Ung Thu' Lǎn Thú' XV. 7-8 October 2010.
14. Marin P,. Coming to terms with Vietnam: Settling our moral debts. Harper's Magazine Dec 1980: 41-56.
15. Suba EJ, Donnelly AD, Furia LM, Huynh MLD, Raab SS,. Viet/American Cervical Cancer Prevention Project. Coming to terms with Vietnam: The Viet/American Cervical Cancer Prevention Project. Diagn Cytopathol 2005; 33: 344-351. (Pubitemid 41598056)
16. October 2004 interview with Nguyên Vúong M.D. Ph.D. (President, Vietnam College of Pathologists; Editor-in-Chief, Vietnam Journal of Medicine). Available at: [last accessed November 1, 2010 ].
17. Glaberson W,. Agent Orange case for millions of Vietnamese is dismissed. New York Times. March 10, 2005. Available at: [last accessed November 1, 2010 ].
18. Kotter JP,. Leading change. Boston, MA: Harvard Business School Press; 2006.
19. Pascale RT, Sternin J, Sternin M,. The power of positive deviance: How the world's most unlikely innovators solve the world's toughest problems. Boston, MA: Harvard Business School Press; 2010.
20. Marsh DR, Schroeder DG, Dearden KA, Sternin J, Sternin M,. The power of positive deviance. BMJ 2004; 329: 1177-1179, review. (Pubitemid 39529772)
21. Suba EJ, Raab SS,. Viet/American Cervical Cancer Prevention Project. Lessons learned from successful Papanicolaou cytology cervical cancer prevention in the Socialist Republic of Vietnam. Hôi Thao Quôc Gia Phéng Chông Ung Thu Lǎn Thú XV. 7-8 October 2010.
22. Suba EJ,. Viet/American Cervical Cancer Prevention Project. Crossing the quality chasm: A requirement for successful cervical cancer prevention in developing countries. Clin Lab Med 2004; 24: 945-963, review. (Pubitemid 39539233)
23. Trung NS,. Professor and Chair of Pathology and Dean, Ho Chi Minh City Medical University. Personal communication, 2009.
24. Solomon D, Breen N, McNeel T,. Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. CA Cancer J Clin 2007; 57: 105-111. (Pubitemid 46535710)
25. McCoy D, Kembhavi G, Patel J, Luintel A,. The Bill & Melinda Gates Foundation's grant-making programme for global health. Lancet 2009; 373: 1645-1653.
26. Suba EJ, Raab SS,. Viet/American Cervical Cancer Prevention Project. Papanicolaou screening in developing countries: An idea whose time has come. Am J Clin Pathol 2004; 121: 315-320. (Pubitemid 38298163)
27. Birn AE,. Gates's grandest challenge: Transcending technology as public health ideology. Lancet 2005; 366: 514-519.
28. World Health Organization. World report on knowledge for better health. Available at: [last accessed November 1, 2010 ].
29. Wright TC, Jr, Blumenthal P, Bradley J, et al. Alliance for Cervical Cancer Prevention. Cervical cancer prevention for all the world's women: New approaches offer opportunities and promise. Diagn Cytopathol 2007; 35: 845-848. (Pubitemid 350250770)
30. Suba EJ, Donnelly AD, Furia LM, Huynh MLD, Raab SS,. Viet/American Cervical Cancer Prevention Project. Cervical cancer prevention for all the world's women: Genuine promise resides in skilled quality management rather than novel screening approaches. Diagn Cytopathol 2007; 35: 187-191. (Pubitemid 46355355)
31. Annan KA, Boufford JI, Cleveland H, et al. In:, Foege WH, editor. Global health leadership and management. San Francisco, CA: Jossey-Bass; 2005. p xvi.
32. U.S. Preventive Services Task Force. Screening for cervical cancer: File inventory. Available at: [last accessed November 1, 2010 ].
33. Sawaya GF,. Evidence-based medicine versus liquid-based cytology. Obstet Gynecol 2008; 111: 2-3.
34. U.S. Preventive Services Task Force. Screening for cervical cancer: Summary of recommendations. Available at: [last accessed November 1, 2010 ].
35. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 87-93. (Pubitemid 30038388)
36. Almonte M, Ferreccio C, Winkler JL, et al. Cervical screening by visual inspection. HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 2007; 121: 796-802. (Pubitemid 47106209)
37. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439-444. (Pubitemid 33033096)
38. Blumenthal PD, Gaffikin L, Chirenje ZM, et al. Adjunctive testing for cervical cancer in low resource settings with visual inspection. HPV, and the Pap smear. Int J Gynaecol Obstet 2001; 72: 47-53. (Pubitemid 32007864)
39. Lynge E, Rebolj M,. Primary HPV screening for cervical cancer prevention: Results from European trials. Nat Rev Clin Oncol 2009; 6: 699-706.
40. Boyes DA, Morrison B, Knox EG, Draper GJ, Miller AB,. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982; 5: 1-29. (Pubitemid 12098797)
41. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with CIN3: A retrospective cohort study. Lancet Oncol 2008; 9: 425-434.
42. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-1392.
43. Austin RM, Zhao C,. Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India. Cytojournal 2009; 6: 12.
44. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-1394.
45. Suba EJ, Cibas ES, Raab SS,. HPV screening in rural India. N Engl J Med 2009; 361: 304; author reply 306.
46. Miller AB,. Cervical cancer in rural India. Nat Rev Clin Oncol 2009; 6: 384-385.
47. Rebolj M, Lynge E,. Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen 2010; 17: 1-2.
48. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936.
49. Handbook of Cancer Prevention, Volume 10: Cervix Cancer Screening. World Health Organization: International Agency for Research on Cancer. Lyon, France: IARC Press; 2005.
50. Testing kits for the molecular detection of human papillomavirus. Available at: [last accessed November 1, 2010 ].
51. Wright TC, Jr,. HPV DNA testing for cervical cancer screening. Int J Gynaecol Obstet 2006; 95 (suppl 1): S239YS46.
52. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-2684. (Pubitemid 44691325)
53. Firnhaber C, Van Le H, Pettifor A, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 2010; 21: 433-443.
54. World Health Organization. Comprehensive cervical cancer control: A guide to essential practice, p 98. Available at: [last accessed November 1, 2010 ].
55. Brewster WR, Hubbell FA, Largent J, et al. Feasibility of management of high-grade cervical lesions in a single visit: A randomized controlled trial. JAMA 2005; 294: 2182-2187. (Pubitemid 41571135)
56. Perkins RB, Langrish SM, Stern LJ, Burgess JF, Simon CJ,. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: The case of Honduras. Womens Health Issues 2010; 20: 35-42.
57. Tsu V,. Reconsidering the feasibility of Pap and alternative screening tests for low resource settings. Am J Public Health 2007; 97: 199, author reply 199-200. (Pubitemid 47279355)
58. Wright TC, Jr,. Chapter 10: Cervical cancer screening using visualization techniques. J Natl Cancer Inst Monogr 2003; 31: 66-71. Review.
59. Gage JC, Castle PE,. Preventing cervical cancer globally by acting locally: If not now, when? J Natl Cancer Inst 2010; 102: 1524-1527.
60. Suba EJ, Michelow PM, Wright CA, Raab SS,. Re: Preventing cervical cancer globally by acting locally: If not now, when? J Natl Cancer Inst, in press.
61. Haug CJ,. Human papillomavirus vaccination-Reasons for caution. N Engl J Med 2008; 359: 861-862.
62. Harper DM,. Preliminary HPV vaccine results for women older than 25 years. Lancet 2009; 373 (9679): 1921-1922.
63. Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D,. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol 2009; 114: 360-364.
64. Haug C,. The risks and benefits of HPV vaccination. JAMA 2009; 302: 795-796.
65. Harper DM,. Gardasil needs a new consent form. Expert Rev Vaccines 2009; 8: 1613-1614.
66. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ,. Exploring the cost-effectiveness of HPV vaccination in Vietnam: Insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26: 4015-4024.
67. Suba EJ, Raab SS,; Viet/American Cervical Cancer Prevention Project. HPV vaccination: Waiting for evidence of effectiveness. Lancet 2010; 375 (9715): 639-640.
68. National Vaccine Injury Compensation Program. Statistics report. Available at: [last accessed November 1, 2010 ].
69. Harper DM,. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009; 8: 1663-1679.
70. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP,. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses. PLoS Med 2006; 3: e138.
71. Michels KB, zur Hausen H,. HPV vaccine for all. Lancet 2009; 374 (9686): 268-270.
72. Suba EJ, Raab SS,; Viet/American Cervical Cancer Prevention Project. Human papillomavirus vaccine. N Engl J Med 2007; 357: 1155; author reply 1155-1156.
73. Sherris J, Wright TC, Denny L, et al. Alliance for cervical cancer prevention: Setting the record straight. Am J Public Health 2007; 97: 200-201, author reply 201-202. (Pubitemid 47279357)
74. Suba EJ, Frable WJ, Raab SS,. Cost-effectiveness of cervical- cancerscreening in five developing countries. N Engl J Med 2006; 354: 1535-1536, author reply 1535-1536.
75. Levin CE, Sellors JW,. De novo establishment and cost-effectiveness of Papanicolaou screening services in the Socialist Republic of Vietnam. Cancer 2002; 94: 2312-2314, author reply 2314-2316.
76. Suba EJ, Raab SS,. Cervical cancer screening in developing countries. JAMA 2001; 286: 3079-3080, author reply 3080-3081.
77. Suba EJ, Geisinger KR, Zarka MA, Raab SS,. Prevention of cervical cancer in low-resource settings. JAMA 2006; 295: 1248-1249, author reply 1249.
78. Internet-based quality management tools for successful cervical cancer prevention in Vietnam and Brazil. Available at: [last accessed November 1, 2010 ].
79. Yamada T,. Global health and the Bill & Melinda Gates Foundation. Lancet 2009; 373: 2195.
80. The questionnaire, accompanied by supporting documentation, was emailed on November 2 2009 to the Bill & Melinda Gates Foundation global health leadership team identified on the Foundation website:, Jan Agosti, William Foege, Karen Miller, Linda Patterson, Regina Rabinovich, Cheryl Scott, Jaime Sepulveda, Rajeev Venkayya, and, Tachi Yamada, X.
81. The Bill & Melinda Gates Foundation. Guiding Principles. Available at: [last accessed November 1, 2010 ].
82. What has the Gates Foundation done for Global Health? Editorial. Lancet 2009; 373: 1577.
83. McNeil DG, Jr,. Gates Foundation's influence criticized. Feb 16, 2008. New York Times. Available at: [last accessed November 1, 2010 ].
84. Jeronimo J, Barone MA, Luciani S, et al. Reply to: Austin et al. (Unfounded claims mar scientific critique). Cytojournal 2009; 6: 23.
85. Ankit J, Prakriti J, Lakshmaiah KC,. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 361: 304-305, author reply 306.
86. Cremer ML, Conlisk E, Felix JC,. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 361: 305, author reply 306.
87. Schiffman M, Wacholder S,. From India to the world-A better way to prevent cervical cancer. N Engl J Med 2009; 360: 1453-1455.
88. Bogdanich W,. Lax laboratories: The Pap test misses much cervical cancer through labs' errors. Wall Street Journal. November 2, 1987: 1.
89. DeMay RM,. The Pap test. Chicago, IL: ASCP Press; 2005.
90. Cohen D, Carter P,. Conflicts of Interest: WHO and the pandemic flu "conspiracies." BMJ 2010; 340: c2912.
91. Saul S, Pollack A,. Furor on rush to require cervical cancer vaccine. New York Times. February 17, 2007. Available at: [last accessed November 1, 2010 ].
92. Rothman SM, Rothman DJ,. Marketing HPV vaccine: Implications for adolescent health and medical professionalism. JAMA 2009; 302: 781-786.
93. Gates Foundation to provide funding for Vietnam HPV vaccination research program. Available at: [last accessed November 1, 2010 ].
94. Piller C,. A sampling of the Gates Foundation's largest investments. Los Angeles Times. January 7, 2007. Available at: <> [last accessed November 1, 2010 ].
95. Hodgson J,. Gates Foundation sells off most health-care, pharmaceutical holdings. Wall Street Journal. August 14, 2009. Available at: [last accessed November 1, 2010 ].
96. Yamada T,. In search of new ideas for global health. N Engl J Med 2008; 358: 1324-1325. (Pubitemid 351468408)
97. National Institutes of Health Office of Technology Transfer. Top 20 commercially successful inventions, fiscal year 2009. Available at: [last accessed November 1, 2010 ].
98. Program for Appropriate Technology in Health. Introducing a vaccine to prevent cervical cancer in Vietnam. Available at: [last accessed October 26, 2010 ].
99. National Institutes of Health/National Cancer Institute. FactSheet regarding HPV vaccines. Available at: [last accessed November 8, 2010 ].
100. Silverman E,. Vietnam investigates approval of HPV vaccines. Available at:. [last accessed November 1, 2010 ].
101. World Health Organization. Position paper on HPV vaccines. Available at: [last accessed November 1, 2010 ].
102. Haas M, Ashton T, Blum K, et al. Drugs, sex, money and power: An HPV vaccine case study. Health Policy 2009; 92: 288-295.
103. Larson HJ, Brocard P, Garnett G,. The India HPV-vaccine suspension. Lancet 2010; 376: 572-573.